MARLBOROUGH, Mass., Jan. 18, 2017 /PRNewswire/ -- Lemelson Capital Management, LLC, a private investment management firm, today announced performance results for its flagship Amvona Fund, LP. 

For 2016, The Amvona Fund returned 84.97 percent net of all fees and expenses, beating by 73 percent the benchmark S&P 500 Total Return Index[1], which returned 11.96 percent during this period.  Since its September 2012 inception, The Amvona Fund, LP, has returned a compounded annualized rate or return of 23.81 percent net of all fees and expenses compared to 13.73 percent for the benchmark S&P 500 Total Return Index.

A few highlights for the firm and fund in 2016 include:

  • Management increased its stake in Geospace Technologies, Inc. (NASDAQ: GEOS) from 5.55 percent of shares outstanding at year end 2015 to 9 percent at the close of 2016.
  • Management substantially increased its short position in Domino's Pizza, Inc. (NYSE: DPZ). As of year-end 2016, Domino's is the largest short position in the fund.
  • In December 2016, management issued a research report to the U.S. Senate Special Committee on Aging and the U.S. Food and Drug Administration (FDA) on abuse of federal regulations and statutes by Ligand Pharmaceuticals, Inc. (NASDAQ: LGND), a U.S.-based pharmaceutical company. In January 2016, the firm filed a whistleblower report with the U.S. Securities and Exchange Commission (SEC) on Ligand's fraudulent accounting practices. Lemelson Capital's letter to the U.S. Senate Special Committee on Aging can be read here

"While the performance of The Amvona Fund, LP, in 2016 was exceptional, investors should not expect this sort of return in the future," said Fr. Emmanuel Lemelson, Chief Investment Officer of Lemelson Capital Management.  "Management's focus will remain on uncovering substantial price-value dislocations to continue to deliver a favorable compounded annualized rate of return to the partnership over the long run."

Further information, including an important notice and disclaimer regarding the fund's performance and this release, can be read here

About Lemelson Capital Management

Lemelson Capital Management, LLC, is a private investment management firm focused on deep value and special situation investments.  Its flagship fund, The Amvona Fund, LP, has been named repeatedly among the world's top performing hedge funds since its September 2012 inception.

To see performance results by year, and read The Amvona Fund's annual and interim reports, visit www.lemelsoncapital.com   

[1] The S&P 500 Total Return Index includes the reinvestment of dividends

For further information, please contact:

Media and Public Relations 
Lemelson Capital Management, LLC 
Telephone: 508-630-2281

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lemelson-capital-management-announces-2016-performance-results-for-the-amvona-fund-lp-300392758.html

SOURCE Lemelson Capital Management, LLC

Copyright 2017 PR Newswire

Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ligand Pharmaceuticals Charts.
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ligand Pharmaceuticals Charts.